Cantor Fitzgerald Analysts Lift Earnings Estimates for NTLA

Intellia Therapeutics, Inc. (NASDAQ:NTLA) – Equities researchers at Cantor Fitzgerald upped their FY2025 earnings estimates for shares of Intellia Therapeutics in a research report issued to clients and investors on Monday, May 12th. Cantor Fitzgerald analyst R. Bienkowski now forecasts that the company will post earnings per share of ($3.83) for the year, up from their prior forecast of ($4.34). The consensus estimate for Intellia Therapeutics’ current full-year earnings is ($5.07) per share.

A number of other equities analysts have also recently issued reports on the company. StockNews.com upgraded Intellia Therapeutics to a “sell” rating in a report on Monday, March 3rd. Guggenheim decreased their price target on Intellia Therapeutics from $55.00 to $45.00 and set a “buy” rating for the company in a research report on Monday. JPMorgan Chase & Co. reiterated a “neutral” rating and issued a $13.00 target price (down from $45.00) on shares of Intellia Therapeutics in a research note on Friday, February 28th. Wolfe Research upgraded Intellia Therapeutics from a “peer perform” rating to an “outperform” rating and set a $21.00 price target for the company in a research note on Monday, April 21st. Finally, Chardan Capital reiterated a “buy” rating and issued a $68.00 price objective on shares of Intellia Therapeutics in a research note on Friday, May 9th. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $36.90.

Intellia Therapeutics Stock Up 2.4%

Shares of NASDAQ NTLA opened at $8.07 on Wednesday. The firm has a market cap of $835.91 million, a PE ratio of -1.48 and a beta of 2.33. The company’s fifty day simple moving average is $8.00 and its 200 day simple moving average is $10.82. Intellia Therapeutics has a 12-month low of $5.90 and a 12-month high of $28.18.

Intellia Therapeutics (NASDAQ:NTLA) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($1.10) earnings per share for the quarter, topping the consensus estimate of ($1.26) by $0.16. The business had revenue of $16.63 million during the quarter, compared to the consensus estimate of $11.39 million. The business’s revenue was down 42.6% on a year-over-year basis. During the same period last year, the business posted ($1.12) earnings per share.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. GF Fund Management CO. LTD. bought a new position in shares of Intellia Therapeutics in the fourth quarter worth approximately $25,000. Northwestern Mutual Wealth Management Co. increased its position in shares of Intellia Therapeutics by 56.4% during the first quarter. Northwestern Mutual Wealth Management Co. now owns 4,590 shares of the company’s stock valued at $33,000 after buying an additional 1,655 shares during the period. Sterling Capital Management LLC raised its position in shares of Intellia Therapeutics by 866.2% in the 4th quarter. Sterling Capital Management LLC now owns 3,198 shares of the company’s stock worth $37,000 after acquiring an additional 2,867 shares in the last quarter. Harbour Investments Inc. raised its holdings in Intellia Therapeutics by 76.7% in the first quarter. Harbour Investments Inc. now owns 5,214 shares of the company’s stock worth $37,000 after purchasing an additional 2,264 shares in the last quarter. Finally, Whipplewood Advisors LLC purchased a new position in Intellia Therapeutics during the 4th quarter valued at about $40,000. 88.77% of the stock is owned by hedge funds and other institutional investors.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.